Navigation Links
Inverness Medical Innovations Announces Third Quarter 2008 Results
Date:10/29/2008

osite, Inc. and Cholestech Corp. during

the second and third quarters of 2007, respectively.

(f) Purchase of in-process research and development during the nine

months ended September 30, 2007 includes a write-off of $169.0

million associated with the value of in-process research and

development costs incurred in connection with our acquisition of

Biosite, Inc.

(g) Charges totaling $15.6 million associated with the write-off of debt

origination costs and a prepayment premium paid upon early

extinguishment of related debt during the nine months ended

September 30, 2007, in conjunction with our financing arrangements.

(h) A $1.7 million net realized foreign currency loss associated with a

cash escrow established in connection with the acquisition of BBI

Holdings Plc.

(i) A $1.9 million foreign currency gain realized on the settlement of

intercompany notes.

(j) Tax effect on adjustments as discussed above in notes (b), ( c ),

(d), (e), (f), (g), (h) and (i).

(k) For the nine months ended September 30, 2008 and 2007, potential

dilutive shares were not used in the calculation of diluted net loss

per common share under GAAP because inclusion thereof would be

antidilutive.

(l) Included in the weighted average diluted common shares for the

calculation of net income per common share for the nine months ended

September 30, 2008, on an adjusted cash basis, are dilutive shares

consisting of 2,349,000 common stock equivalent shares from the

potential exercise of stock options and warrants and potential

dilutive shares consisting of 3,411,000 common stock equivalent

shares from the potential conversion of convertible debt securities.

The net income per dilute
'/>"/>

SOURCE Inverness Medical Innovations, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET October 29, 2008 to Discuss Third Quarter 2008 Results
2. Inverness Medical Innovations to Present at the UBS Global Life Sciences Conference on September 22, 2008
3. Inverness Medical Innovations to Attend the Goldman Sachs Diagnostics Conference on September 18, 2008
4. Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Preferred Stock
5. Inverness Medical Innovations to Present at the Morgan Stanley Global Healthcare Unplugged Conference on September 9, 2008
6. Inverness Medical Innovations Features Innovative TB Diagnostic - Clearview(R) TB ELISA at AIDS 2008
7. Inverness Medical Innovations to Present at Canaccord Adams 28th Annual Growth Conference on August 12, 2008
8. Inverness Medical Innovations Announces Second Quarter 2008 Results
9. Inverness Medical Innovations to Present at Jefferies 2nd Annual Healthcare Conference held on June 25, 2008
10. Inverness Medical Innovations to Present at 7th Annual Needham & Company, LLC Biotechnology & Medical Technology Conference on June 12, 2008
11. Inverness Medical Innovations to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 28, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2014)... December 12, 2014 Trend lines for ... overall global economic growth, Eugene Arthurs, CEO of ... said in a featured talk at OPTIC (Optics and ... the National Chung Hsing University in Taichung. , As ... into future energy supplies and soon to hit US$50 ...
(Date:12/13/2014)... 13, 2014 According to population studies: ... between now and 2030." If a population explosion like ... most populous state in the country. , To that ... the Future of North Carolina Forum on December 16th ... have the necessary infrastructure in place? Enough clean water? ...
(Date:12/13/2014)... -- Vermillion, Inc. (NasdaqCM: VRML), a bio-analytical solutions company focused on ... G. H. Jordan , Ph.D., and David R. ... the total number of directors to eight, seven of ... , Chairman, President, and Chief Executive Officer of Vermillion, ... of Veronica and David to our board of directors.  ...
(Date:12/13/2014)... , Dec. 12, 2014  Vaccinex Inc., ... discovery and development of therapeutic monoclonal antibodies ... announced publication of a manuscript entitled "SEMA4D ... remyelination in neurodegenerative disease" in the January ... Disease*.  The publication highlights an important role ...
Breaking Biology Technology:Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 2Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 3Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 4Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 5North Carolina Chamber of Commerce: Asking Questions & Gathering Answers with a Futurist 2Vermillion Strengthens Board of Directors with Appointments of Veronica Jordan, Ph.D., and David Schreiber 2Vermillion Strengthens Board of Directors with Appointments of Veronica Jordan, Ph.D., and David Schreiber 3Vaccinex announces publication of preclinical studies with an anti-SEMA4D antibody in animal models of neuroinflammatory and demyelinating disease 2
... Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer ... bioimplants processed from human amniotic membrane, announced today ... Systagenix, whereby Systagenix will co-market EpiFix®. The MiMedx ... amniotic tissue, EpiFix® offers a wide variety of ...
... first Minority Biomedical Entrepreneurship Conference (MBEC), will convene ... platform for minority professionals, entrepreneurs, investors, students and ... ideas. (Logo: http://photos.prnewswire.com/prnh/20120319/DC71722LOGO ) ... of the growing biomedical industry workforce, and a ...
... DIEGO and PHILADELPHIA, March 19, 2012 Toby Odenheim, director ... contract research organization (CRO), is slated to present on ... at the Outsourcing in Clinical Trials, East Coast ... Odenheim will speak at 11 a.m. EDT, Wed., March 28, ...
Cached Biology Technology:MiMedx Signs Agreement with Systagenix for Global Distribution of EpiFix® 2MiMedx Signs Agreement with Systagenix for Global Distribution of EpiFix® 3Minority Biomedical Entrepreneurship Conference 2Minority Biomedical Entrepreneurship Conference 3Synteract Director of IT Services Toby Odenheim Speaking at March 2012 Outsourcing in Clinical Trials East Coast Conference 2Synteract Director of IT Services Toby Odenheim Speaking at March 2012 Outsourcing in Clinical Trials East Coast Conference 3
(Date:12/5/2014)... 2014 Increased emphasis on product quality, ... testing and inspection technologies. The convergence of industries ... range of innovative test solutions. This trend is ... which is generally more inclined towards communication, media ... strategies of test equipment vendors will cater to ...
(Date:12/4/2014)... PALM BEACH GARDENS, Fla. , Dec. 3, ... identity management solutions, today announced that its DigitalPersona ... 4500 fingerprint readers have been deployed throughout ... Carolina , South Carolina ... network headquartered in Southern Pines, North ...
(Date:12/3/2014)... 2014 As part of our commitment to ... pleased to announce the release of a new reader ... the workforce data that they need. The ... by existing readers. Many such devices have serious shortcomings ... technology. Older models force users to navigate numerous complicated ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Inception Technologies to Release New Biometric Reader 2
... using a novel technique to better understand mineral growth ... Ridge National Laboratory are improving predictions of mineral reactions ... oil pipes clear to sequestering radium. The mineral ... generally, but also because it is the dominant scale-forming ...
... SUNY Downstate Medical Center,s growth into a major center ... awarded SUNY Downstate a four-year challenge grant of $220,000 ... causes, treatment, and prevention of blinding diseases. Douglas R. ... principal investigator. RPB is the world,s leading voluntary organization ...
... one of the most common neurological diseases, more than 4,000 ... decoded over the next five years in a study led ... and several collaborating institutions. Daniel Lowenstein, MD , ... been attempted for identifying the genetic causes of epilepsy, and ...
Cached Biology News:Metadynamics technique offers insight into mineral growth and dissolution 2SUNY Downstate receives grant from research to prevent blindness 2UCSF shares $25-million grant to find epilepsy genes 2UCSF shares $25-million grant to find epilepsy genes 3
... serum is extensively scrutinized, including ... All horses are of ... worming are controlled and documented ... consistency. Pricing: $12/unit ...
... new primer sets added in Dec 2005 ... hours , Detection from as little ... Specific primers available for hundreds of mammalian ... or end-point RT-PCR , Ideal for ...
jub, ajuba homolog (Xenopus laevis)...
Recommend to use at up to 5000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.)...
Biology Products: